XBiotech Inc
NASDAQ:XBIT
Intrinsic Value
XBiotech, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutic antibodies. [ Read More ]
The intrinsic value of one XBIT stock under the Base Case scenario is 3.56 USD. Compared to the current market price of 8.74 USD, XBiotech Inc is Overvalued by 59%.
Valuation Backtest
XBiotech Inc
Run backtest to discover the historical profit from buying and selling XBIT stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
XBiotech Inc
Current Assets | 201.7m |
Cash & Short-Term Investments | 200m |
Receivables | 935k |
Other Current Assets | 760k |
Non-Current Assets | 24.9m |
PP&E | 24.9m |
Current Liabilities | 6.1m |
Accounts Payable | 2.5m |
Accrued Liabilities | 3.5m |
Other Current Liabilities | 83k |
Non-Current Liabilities | 1.7m |
Other Non-Current Liabilities | 1.7m |
Earnings Waterfall
XBiotech Inc
Revenue
|
0
USD
|
Operating Expenses
|
-37.5m
USD
|
Operating Income
|
-37.5m
USD
|
Other Expenses
|
13m
USD
|
Net Income
|
-24.6m
USD
|
Free Cash Flow Analysis
XBiotech Inc
XBIT Profitability Score
Profitability Due Diligence
XBiotech Inc's profitability score is 21/100. The higher the profitability score, the more profitable the company is.
Score
XBiotech Inc's profitability score is 21/100. The higher the profitability score, the more profitable the company is.
XBIT Solvency Score
Solvency Due Diligence
XBiotech Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Score
XBiotech Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
XBIT Price Targets Summary
XBiotech Inc
According to Wall Street analysts, the average 1-year price target for XBIT is 18 USD .
Ownership
XBIT Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
XBIT Price
XBiotech Inc
Average Annual Return | -0.79% |
Standard Deviation of Annual Returns | 78.83% |
Max Drawdown | -88% |
Market Capitalization | 266m USD |
Shares Outstanding | 30 457 500 |
Percentage of Shares Shorted | 3.98% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
XBiotech, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutic antibodies. The company is headquartered in Austin, Texas and currently employs 97 full-time employees. The company went IPO on 2015-04-15. The firm is focused on the therapies that block a potent substance naturally produced by body, known as interleukin-1 alpha (IL-1a), that mediates tissue breakdown, angiogenesis, the formation of blood clots and inflammation. IL-1a is a protein that is on or in cells of the body and is involved in the body’s response to injury or trauma. Its True Human antibodies have the potential to harness the body's natural immunity to fight disease with increased safety, efficacy and tolerability. The firm has developed a pipeline of product candidates targeting both inflammatory and infectious diseases. The firm is developing a pipeline of product candidates targeting both inflammatory and infectious diseases and has developed commercial scale manufacturing technology and infrastructure.
Contact
IPO
Employees
Officers
The intrinsic value of one XBIT stock under the Base Case scenario is 3.56 USD.
Compared to the current market price of 8.74 USD, XBiotech Inc is Overvalued by 59%.